Fulcrum Therapeutics, Inc. FULC

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contributing its drug assets, while new investors are supplying $245 million. Legacy Slate holders would own approximately 55.9% of the combined company, PIPE investors 39.1%, and legacy Fulcrum holders 5%, […]

After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec

Fulcrum Therapeutics (FULC) and Slate Medicines said Monday they have agreed to combine in an all-st

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclonal antibody for the preventative treatment of migraine Concurrent oversubscribed private placement financing of $245 million from a leading syndicate of healthcare investors anticipated to fund operations into 2029 Companies to hold conference c

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...

For Fulcrum Therapeutics, the modeled fair value has been reset from about US$19.00 to roughly US$5.43, a cut of around 71% that pulls implied price targets sharply lower. Much of this reset aligns with recent analyst commentary that focuses on the discontinuation of pociredir, class wide PRC2 safety concerns, and a shift to viewing the stock mainly through its cash position and review of strategic alternatives. As you read on, you will see how this evolving narrative is shaping expectations...

A Cambridge biotech company is laying off 85% of staff and ending its sickle cell drug after the FDA cited unacceptable cancer risks linked to its drug class.

Why Fulcrum Therapeutics Stock Is Back in Focus Fulcrum Therapeutics (FULC) is back on investors' radar after the company scrapped development of its lead sickle cell disease drug, pociredir, and moved quickly into a deep restructuring and review of options. See our latest analysis for Fulcrum Therapeutics. The discontinuation of pociredir and the sweeping restructuring have driven sharp volatility. The stock is down about 52% on a 1 year total shareholder return basis. The 3 year total...